- HALIX B.V. has appointed Dr. Lutz Hilbrich as its new CEO, effective immediately.
- Dr. Hilbrich brings over 20 years of experience in biopharmaceutical development and manufacturing.
HALIX B.V., a contract development and manufacturing organisation (CDMO), has announced the appointment of Dr. Lutz Hilbrich as its new Chief Executive Officer. The appointment, effective immediately, follows the successful leadership of Alex Huybens, who previously led the company’s activities.
Dr. Hilbrich joins HALIX with more than two decades of experience in biotechnology and pharmaceuticals. He has held leadership roles across the globe, including regions such as the US, China, Europe, and Africa, driving operational excellence and business transformation. “I am honoured to join HALIX at such an exciting time in the company’s journey,” Dr. Hilbrich said. “I am eager to work with the talented team at HALIX to build on this strong foundation.”
Based in Leiden, HALIX specialises in developing and manufacturing viral vectors, recombinant proteins, and other complex biopharmaceutical products for clinical and commercial use. The company’s most notable recent work includes partnering with AstraZeneca to manufacture its COVID-19 vaccine.
Dr. Harry Flore, Chairman of the Supervisory Board, expressed confidence in the new leadership: “His extensive experience in biosimilars, cell & gene therapy, and vaccines positions him well to lead HALIX into its next phase of growth.” Flore also thanked outgoing CEO Alex Huybens for his leadership and contributions to the company’s development.
